Journal Article
. 2009 Dec;11(1).
doi: 10.1016/S1470-2045(09)70314-6.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Kathy S Albain 1 William E Barlow  Steven Shak  Gabriel N Hortobagyi  Robert B Livingston  I-Tien Yeh  Peter Ravdin  Roberto Bugarini  Frederick L Baehner  Nancy E Davidson  George W Sledge  Eric P Winer  Clifford Hudis  James N Ingle  Edith A Perez  Kathleen I Pritchard  Lois Shepherd  Julie R Gralow  Carl Yoshizawa  D Craig Allred  C Kent Osborne  Daniel F Hayes  Breast Cancer Intergroup of North America  
Affiliations
  • PMID: 20005174
  •     28 References
  •     407 citations

Abstract

Background: The 21-gene recurrence score assay is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score predicts little benefit of chemotherapy. For node-positive breast cancer, we investigated whether the recurrence score was prognostic in women treated with tamoxifen alone and whether it identified those who might not benefit from anthracycline-based chemotherapy, despite higher risks of recurrence.

Methods: The phase 3 trial SWOG-8814 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) before tamoxifen (CAF-T) added survival benefit to treatment with tamoxifen alone. Optional tumour banking yielded specimens for determination of recurrence score by RT-PCR. In this retrospective analysis, we assessed the effect of recurrence score on disease-free survival by treatment group (tamoxifen vs CAF-T) using Cox regression, adjusting for number of positive nodes.

Findings: There were 367 specimens (40% of the 927 patients in the tamoxifen and CAF-T groups) with sufficient RNA for analysis (tamoxifen, n=148; CAF-T, n=219). The recurrence score was prognostic in the tamoxifen-alone group (p=0.006; hazard ratio [HR] 2.64, 95% CI 1.33-5.27, for a 50-point difference in recurrence score). There was no benefit of CAF in patients with a low recurrence score (score <18; log-rank p=0.97; HR 1.02, 0.54-1.93), but an improvement in disease-free survival for those with a high recurrence score (score > or =31; log-rank p=0.033; HR 0.59, 0.35-1.01), after adjustment for number of positive nodes. The recurrence score by treatment interaction was significant in the first 5 years (p=0.029), with no additional prediction beyond 5 years (p=0.58), although the cumulative benefit remained at 10 years. Results were similar for overall survival and breast-cancer-specific survival.

Interpretation: The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence score. A low recurrence score identifies women who might not benefit from anthracycline-based chemotherapy, despite positive nodes.

Funding: National Cancer Institute and Genomic Health.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG).
J Natl Cancer Inst, 2002 Jul 18; 94(14). PMID: 12122096
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Stella Mook, Marjanka K Schmidt, +10 authors, TRANSBIG Consortium.
Breast Cancer Res Treat, 2008 Jul 29; 116(2). PMID: 18661261
Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.
Patrick Royston, Mahesh K B Parmar.
Stat Med, 2002 Sep 05; 21(15). PMID: 12210632
Highly Cited.
REporting recommendations for tumour MARKer prognostic studies (REMARK).
L M McShane, D G Altman, +4 authors, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.
Br J Cancer, 2005 Aug 18; 93(4). PMID: 16106245    Free PMC article.
Highly Cited.
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Kathy S Albain, Soonmyung Paik, Laura van't Veer.
Breast, 2009 Nov 17; 18 Suppl 3. PMID: 19914534
Review.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Bernard Fisher, Jong-Hyeon Jeong, +5 authors, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet, 2004 Sep 08; 364(9437). PMID: 15351193
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D C Allred, J M Harvey, M Berardo, G M Clark.
Mod Pathol, 1998 Mar 21; 11(2). PMID: 9504686
Highly Cited. Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Gene expression profiling of breast cancer: a new tumor marker.
Laura J van't Veer, Soonmyung Paik, Daniel F Hayes.
J Clin Oncol, 2005 Mar 10; 23(8). PMID: 15755970
Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
HER2 and response to paclitaxel in node-positive breast cancer.
Daniel F Hayes, Ann D Thor, +14 authors, Cancer and Leukemia Group B (CALGB) Investigators.
N Engl J Med, 2007 Oct 12; 357(15). PMID: 17928597
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Judith-Anne W Chapman, Daniel Meng, +6 authors, Paul E Goss.
J Natl Cancer Inst, 2008 Feb 14; 100(4). PMID: 18270335    Free PMC article.
Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.
Ruth Oratz, Dev Paul, Allen L Cohn, Scot M Sedlacek.
J Oncol Pract, 2007 Jul 01; 3(4). PMID: 20859407    Free PMC article.
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
J M Bull, D C Tormey, +5 authors, R Simon.
Cancer, 1978 May 01; 41(5). PMID: 348293
International Web-based consultation on priorities for translational breast cancer research.
Mitch Dowsett, Aron Goldhirsch, +3 authors, Giuseppe Viale.
Breast Cancer Res, 2007 Nov 24; 9(6). PMID: 18034879    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
A Goldhirsch, W C Wood, +4 authors, 10th St. Gallen conference.
Ann Oncol, 2007 Aug 07; 18(7). PMID: 17675394
Highly Cited. Review.
Revision of the American Joint Committee on Cancer staging system for breast cancer.
S Eva Singletary, Craig Allred, +17 authors, Frederick L Greene.
J Clin Oncol, 2002 Aug 31; 20(17). PMID: 12202663
Highly Cited.
Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer.
Enrique Espinosa, Iker Sánchez-Navarro, +9 authors, Juan Angel Fresno Vara.
PLoS One, 2009 Jun 24; 4(6). PMID: 19547727    Free PMC article.
Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures.
James Chen, Lee Sam, +5 authors, Yves A Lussier.
J Biomed Inform, 2010 Mar 31; 43(3). PMID: 20350617    Free PMC article.
Review of the clinical studies using the 21-gene assay.
Catherine M Kelly, Ellen Warner, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421266    Free PMC article.
Review.
What should physicians look for in evaluating prognostic gene-expression signatures?
Jyothi Subramanian, Richard Simon.
Nat Rev Clin Oncol, 2010 Apr 28; 7(6). PMID: 20421890
Review.
Gene-expression-based prognostic assays for breast cancer.
Chungyeul Kim, Soonmyung Paik.
Nat Rev Clin Oncol, 2010 May 05; 7(6). PMID: 20440284
Review.
Molecular basis for therapy resistance.
Per E Lønning.
Mol Oncol, 2010 May 15; 4(3). PMID: 20466604    Free PMC article.
Review.
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.
Charles Ferté, Fabrice André, Jean-Charles Soria.
Nat Rev Clin Oncol, 2010 Jun 17; 7(7). PMID: 20551944
Review.
Genomic index of sensitivity to endocrine therapy for breast cancer.
W Fraser Symmans, Christos Hatzis, +13 authors, Lajos Pusztai.
J Clin Oncol, 2010 Aug 11; 28(27). PMID: 20697068    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Breast cancer assessment tools and optimizing adjuvant therapy.
Catherine Oakman, Libero Santarpia, Angelo Di Leo.
Nat Rev Clin Oncol, 2010 Oct 27; 7(12). PMID: 20975745
Review.
Chemoendocrine Treatment Is Standard in Hormone Receptor-Positive Patients.
Volkmar Müller.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076601    Free PMC article.
Prostate cancer genomic signature offers prognostic value.
Sarah M Troutman, Douglas K Price, William D Figg.
Cancer biology & therapy, 2010 Nov 20; 10(11). PMID: 21088497    Free PMC article.
Are current development programs realising the full potential of new agents?
Per Eystein Lønning.
Breast Cancer Res, 2011 Jan 05; 12 Suppl 4. PMID: 21172086    Free PMC article.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Breast cancer in 2010: Novel targets and therapies for a personalized approach.
Michaela J Higgins, José Baselga.
Nat Rev Clin Oncol, 2011 Feb 01; 8(2). PMID: 21278769
Review.
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
S Aebi, Z Sun, +14 authors, A Goldhirsch.
Ann Oncol, 2011 Feb 02; 22(9). PMID: 21282282    Free PMC article.
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Armando E Giuliano, Kelly K Hunt, +7 authors, Monica Morrow.
JAMA, 2011 Feb 10; 305(6). PMID: 21304082    Free PMC article.
Highly Cited.
Measuring the performance of markers for guiding treatment decisions.
Holly Janes, Margaret S Pepe, Patrick M Bossuyt, William E Barlow.
Ann Intern Med, 2011 Feb 16; 154(4). PMID: 21320940    Free PMC article.
Multidimensionality of microarrays: statistical challenges and (im)possible solutions.
Stefan Michiels, Andrew Kramar, Serge Koscielny.
Mol Oncol, 2011 Feb 26; 5(2). PMID: 21349780    Free PMC article.
Review.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
Early breast cancer in the older woman.
Sonal Gandhi, Sunil Verma.
Oncologist, 2011 Mar 19; 16(4). PMID: 21415085    Free PMC article.
Review.
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.
Carmen Criscitiello, Debora Fumagalli, Kamal S Saini, Sherene Loi.
Onco Targets Ther, 2011 May 10; 4. PMID: 21552410    Free PMC article.
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Matthew J Ellis, Vera J Suman, +17 authors, John A Olson.
J Clin Oncol, 2011 May 11; 29(17). PMID: 21555689    Free PMC article.
Highly Cited.
Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting.
Ian K Komenaka, Michael L Hibbard, +4 authors, Chandra Jha.
Oncologist, 2011 May 12; 16(6). PMID: 21558133    Free PMC article.
Preoperative chemotherapy for operable breast cancer is associated with better compliance with adjuvant therapy in matched stage II and IIIA patients.
Ian K Komenaka, Chiu-Hsieh Hsu, +6 authors, Chandra Jha.
Oncologist, 2011 May 12; 16(6). PMID: 21558134    Free PMC article.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Christos Hatzis, Lajos Pusztai, +27 authors, W Fraser Symmans.
JAMA, 2011 May 12; 305(18). PMID: 21558518    Free PMC article.
Highly Cited.
All nodes lead to chemo...
Lidia Schapira, Michaela J Higgins.
Oncologist, 2011 May 19; 16(5). PMID: 21586662    Free PMC article.
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.
Jennifer S Haas, Su-Ying Liang, +3 authors, Kathryn A Phillips.
Breast Cancer Res Treat, 2011 Jun 18; 130(2). PMID: 21681446    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
Ruth Oratz, Benjamin Kim, +4 authors, Michael Broder.
J Oncol Pract, 2011 Jul 07; 7(2). PMID: 21731516    Free PMC article.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
Review.
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
Arif H Kamal, Charles L Loprinzi, +7 authors, Matthew P Goetz.
Oncologist, 2011 Sep 22; 16(10). PMID: 21934103    Free PMC article.
A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.
Dong-Yu Wang, Susan J Done, +3 authors, Wey Liang Leong.
Breast Cancer Res, 2011 Sep 24; 13(5). PMID: 21939527    Free PMC article.
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
H Wong, S Lau, +6 authors, T Yau.
Med Oncol, 2011 Oct 11; 29(3). PMID: 21983862
Use of Oncotype DX in Women with Node-Positive Breast Cancer.
Naoko Ishibe, Sheri Schully, Andrew Freedman, Scott David Ramsey.
PLoS Curr, 2011 Oct 11; 3. PMID: 21984342    Free PMC article.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Impact of multigene assays in early stage breast cancer.
Shelly S Lo, Kathy S Albain.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016475    Free PMC article.
Proteomics in melanoma biomarker discovery: great potential, many obstacles.
Michael S Sabel, Yashu Liu, David M Lubman.
Int J Proteomics, 2011 Nov 16; 2011. PMID: 22084682    Free PMC article.
Biomarkers and the genetics of early neoplastic lesions.
Sudhir Srivastava, William E Grizzle.
Cancer Biomark, 2011 Nov 25; 9(1-6). PMID: 22112469    Free PMC article.
Review.
Biologic characteristics of premalignant breast disease.
Kimberly Cole, Maria Tabernero, Karen S Anderson.
Cancer Biomark, 2011 Nov 25; 9(1-6). PMID: 22112476    Free PMC article.
Practical implications of gene-expression-based assays for breast oncologists.
Aleix Prat, Matthew J Ellis, Charles M Perou.
Nat Rev Clin Oncol, 2011 Dec 07; 9(1). PMID: 22143140    Free PMC article.
Highly Cited. Review.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Luminal-B breast cancer and novel therapeutic targets.
Ben Tran, Philippe L Bedard.
Breast Cancer Res, 2012 Jan 06; 13(6). PMID: 22217398    Free PMC article.
Review.
Gene expression profiling: changing face of breast cancer classification and management.
Robert Wesolowski, Bhuvaneswari Ramaswamy.
Gene Expr, 2012 Jan 25; 15(3). PMID: 22268293    Free PMC article.
Review.
Assessing treatment-selection markers using a potential outcomes framework.
Ying Huang, Peter B Gilbert, Holly Janes.
Biometrics, 2012 Feb 04; 68(3). PMID: 22299708    Free PMC article.
Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.
Sarah C Baumgarten, Jonna Frasor.
Mol Endocrinol, 2012 Feb 04; 26(3). PMID: 22301780    Free PMC article.
Review.
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
Shannon Puhalla, Saveri Bhattacharya, Nancy E Davidson.
Mol Oncol, 2012 Mar 13; 6(2). PMID: 22406404    Free PMC article.
Review.
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Stian Knappskog, Ranjan Chrisanthar, +8 authors, Per E Lønning.
Breast Cancer Res, 2012 Mar 17; 14(2). PMID: 22420423    Free PMC article.
Patients with positive axillary lymph nodes: how to use genomic assays.
Ruta Rao.
Curr Treat Options Oncol, 2012 Mar 20; 13(2). PMID: 22426945
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
S Barton, L Zabaglo, +6 authors, M Dowsett.
Br J Cancer, 2012 Apr 26; 106(11). PMID: 22531639    Free PMC article.
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
A Prat, J S Parker, +9 authors, C M Perou.
Ann Oncol, 2012 Apr 26; 23(11). PMID: 22532584    Free PMC article.
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Lawrence J Solin, Robert Gray, +10 authors, Joseph A Sparano.
Breast Cancer Res Treat, 2012 May 02; 134(2). PMID: 22547108    Free PMC article.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.
Per E Lønning.
Ther Adv Med Oncol, 2012 May 17; 4(3). PMID: 22590486    Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, +18 authors, UNICANCER Breast Group.
Oncologist, 2012 May 23; 17(7). PMID: 22610153    Free PMC article.
Strategies for the discovery and development of therapies for metastatic breast cancer.
Bedrich L Eckhardt, Prudence A Francis, Belinda S Parker, Robin L Anderson.
Nat Rev Drug Discov, 2012 Jun 02; 11(6). PMID: 22653217
Highly Cited. Review.
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis.
Masoud H Manjili, Kayvan Najarian, Xiang-Yang Wang.
Future Oncol, 2012 Jul 07; 8(6). PMID: 22764768    Free PMC article.
Review.
Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer.
J Behav Med, 2012 Aug 11; 36(6). PMID: 22878783    Free PMC article.
From drug discovery to biomarker-driven clinical trials in lymphoma.
Anas Younes, Donald A Berry.
Nat Rev Clin Oncol, 2012 Sep 12; 9(11). PMID: 22965151    Free PMC article.
Review.
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
William B Wong, Scott D Ramsey, +2 authors, David L Veenstra.
Contemp Clin Trials, 2012 Sep 18; 33(6). PMID: 22981891    Free PMC article.
Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women's Cancer Initiative - Tata Memorial Hospital (WCI-TMH) Conference.
Anusheel Munshi, Sudeep Gupta, +12 authors, other Locoregional Panel Members.
Indian J Med Paediatr Oncol, 2012 Sep 19; 33(2). PMID: 22988354    Free PMC article.
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor-positive, one-to-three positive axillary lymph node, breast cancer.
M B Hannouf, M Brackstone, B Xie, G S Zaric.
Curr Oncol, 2012 Nov 13; 19(5). PMID: 23144580    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
Aleix Prat, Maggie Chon U Cheang, +8 authors, Charles M Perou.
J Clin Oncol, 2012 Dec 13; 31(2). PMID: 23233704    Free PMC article.
Highly Cited.
Positive expression of Lin28 is correlated with poor survival in gastric carcinoma.
Chaoyang Xu, Jiangguo Shen, +3 authors, Linbo Wang.
Med Oncol, 2013 Jan 08; 30(1). PMID: 23292830
The genomic landscape of breast cancer as a therapeutic roadmap.
Matthew J Ellis, Charles M Perou.
Cancer Discov, 2013 Jan 16; 3(1). PMID: 23319768    Free PMC article.
Highly Cited.
Gene signatures in breast cancer: current and future uses.
Enrique Espinosa Arranz, Juan Ángel Fresno Vara, Angelo Gámez-Pozo, Pilar Zamora.
Transl Oncol, 2013 Jan 17; 5(6). PMID: 23323153    Free PMC article.
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, +9 authors, C Swanton.
Ann Oncol, 2013 Jan 23; 24(3). PMID: 23337633    Free PMC article.
Translating metastasis-related biomarkers to the clinic--progress and pitfalls.
François-Clément Bidard, Jean-Yves Pierga, Jean-Charles Soria, Jean Paul Thiery.
Nat Rev Clin Oncol, 2013 Feb 06; 10(3). PMID: 23381003
Review.
Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?
Olga Golubnitschaja, Kristina Yeghiazaryan, +5 authors, Hans H Schild.
EPMA J, 2013 Feb 20; 4(1). PMID: 23418957    Free PMC article.
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Miguel Martín, Aleix Prat, +24 authors, Philip S Bernard.
Breast Cancer Res Treat, 2013 Feb 21; 138(2). PMID: 23423445    Free PMC article.
Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Elizabeth Spellman, Nadiyah Sulayman, +4 authors, Suzanne C O'Neill.
Psychooncology, 2013 Mar 01; 22(9). PMID: 23447452    Free PMC article.
Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.
Russell M Medford, T Forcht Dagi, Robert S Rosenson, Margaret K Offermann.
Curr Atheroscler Rep, 2013 Mar 21; 15(5). PMID: 23512605
Review.
Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.
Ksenija Kanjer, Svetislav Tatić, +2 authors, Dragica Nikolić-Vukosavljević.
Pathol Oncol Res, 2013 Mar 26; 19(3). PMID: 23526163
Development and validation of a 32-gene prognostic index for prostate cancer progression.
Chin-Lee Wu, Brock E Schroeder, +8 authors, W Scott McDougal.
Proc Natl Acad Sci U S A, 2013 Mar 28; 110(15). PMID: 23533275    Free PMC article.
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
Jeffrey B Smerage, G Thomas Budd, +9 authors, Daniel F Hayes.
Mol Oncol, 2013 Mar 30; 7(3). PMID: 23538216    Free PMC article.
Building a personalized medicine infrastructure at a major cancer center.
Funda Meric-Bernstam, Carol Farhangfar, John Mendelsohn, Gordon B Mills.
J Clin Oncol, 2013 Apr 17; 31(15). PMID: 23589548    Free PMC article.
Review.
Breast cancer genomics: challenges in interpretation and application.
Cathy M Kelly, W Fraser Symmans, Eleni Andreopoulou, Giampaolo Bianchini.
Oncologist, 2013 May 02; 18(4). PMID: 23633449    Free PMC article.
Identification and validation of a new set of five genes for prediction of risk in early breast cancer.
Giorgio Mustacchi, Maria Pia Sormani, +5 authors, Luca Morandi.
Int J Mol Sci, 2013 May 08; 14(5). PMID: 23648477    Free PMC article.
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.
Scott D Ramsey, Sean D Sullivan, +12 authors, Art Small.
Oncologist, 2013 May 08; 18(6). PMID: 23650020    Free PMC article.
First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Debu Tripathy, Peter A Kaufman, +6 authors, Hope S Rugo.
Oncologist, 2013 May 09; 18(5). PMID: 23652380    Free PMC article.
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
S Holt, G Bertelli, +12 authors, C J Phillips.
Br J Cancer, 2013 May 23; 108(11). PMID: 23695023    Free PMC article.
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
Salomon M Stemmer, Shmuel H Klang, +7 authors, Nicky Lieberman.
Breast Cancer Res Treat, 2013 Jun 27; 140(1). PMID: 23801158    Free PMC article.
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Dennis C Sgroi, Erin Carney, +16 authors, Paul E Goss.
J Natl Cancer Inst, 2013 Jul 03; 105(14). PMID: 23812955    Free PMC article.
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Amanda Eustace, Navin Mani, +12 authors, Catharine M L West.
Clin Cancer Res, 2013 Jul 04; 19(17). PMID: 23820108    Free PMC article.
Cellular iron metabolism in prognosis and therapy of breast cancer.
Suzy V Torti, Frank M Torti.
Crit Rev Oncog, 2013 Jul 25; 18(5). PMID: 23879588    Free PMC article.
Review.
Luminal breast cancer: from biology to treatment.
Michail Ignatiadis, Christos Sotiriou.
Nat Rev Clin Oncol, 2013 Jul 25; 10(9). PMID: 23881035
Review.
Who gets genomic testing for breast cancer recurrence risk?
J T DeFrank, T Salz, K Reeder-Hayes, N T Brewer.
Public Health Genomics, 2013 Aug 01; 16(5). PMID: 23899493    Free PMC article.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Clara Chen, Rahul Dhanda, +2 authors, Debra A Patt.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942918    Free PMC article.
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.
Otto Metzger-Filho, Aurélie Catteau, +21 authors, Christos Sotiriou.
PLoS One, 2013 Aug 31; 8(8). PMID: 23990869    Free PMC article.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Giampaolo Bianchini, Lajos Pusztai, +16 authors, Luca Gianni.
Breast Cancer Res, 2013 Sep 26; 15(5). PMID: 24060333    Free PMC article.
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Takayuki Ueno, Norikazu Masuda, +12 authors, Masakazu Toi.
Int J Clin Oncol, 2013 Oct 09; 19(4). PMID: 24101215
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Dejan Knezevic, Audrey D Goddard, +8 authors, Christopher Quale.
BMC Genomics, 2013 Oct 10; 14. PMID: 24103217    Free PMC article.
Highly Cited.
An unmet need: tailoring extended adjuvant endocrine therapy.
G Bianchini, L Gianni.
Br J Cancer, 2013 Nov 21; 109(12). PMID: 24253504    Free PMC article.
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Suzanne A Eccles, Eric O Aboagye, +84 authors, Alastair M Thompson.
Breast Cancer Res, 2013 Nov 30; 15(5). PMID: 24286369    Free PMC article.
Highly Cited. Review.
Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
Pharmacoeconomics, 2013 Nov 30; 32(2). PMID: 24288208
The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy.
Nava Siegelmann-Danieli, Barbara Silverman, +3 authors, Avi Porath.
Ecancermedicalscience, 2014 Jan 05; 7. PMID: 24386009    Free PMC article.
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).
Tadahiko Shien, Hiroji Iwata, +7 authors, Haruhiko Fukuda.
Int J Clin Oncol, 2014 Jan 08; 19(6). PMID: 24395447
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Reply to E.J. Moylan et al.
Sandra M Swain, Gong Tang, Charles E Geyer.
J Clin Oncol, 2014 Jan 15; 32(6). PMID: 24419136    Free PMC article.
The application of Oncotype DX in early-stage lymph-node-positive disease.
Sarika Jain, William J Gradishar.
Curr Oncol Rep, 2014 Jan 21; 16(1). PMID: 24442572
Review.
Timing of determining axillary lymph node status when neoadjuvant chemotherapy is used.
Eleftherios P Mamounas.
Curr Oncol Rep, 2014 Jan 22; 16(2). PMID: 24445496    Free PMC article.
Review.
Oncotype dx results in multiple primary breast cancers.
Michael J Toole, Kelley M Kidwell, Catherine Van Poznak.
Breast Cancer (Auckl), 2014 Jan 24; 8. PMID: 24453493    Free PMC article.
Reply to: prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer.
A Goldhirsch, A S Coates.
Ann Oncol, 2014 Jan 25; 25(3). PMID: 24458471    Free PMC article.
Molecular tests as prognostic factors in breast cancer.
Marc J van de Vijver.
Virchows Arch, 2014 Feb 04; 464(3). PMID: 24487789
Review.
Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved.
M Schmidt, M Untch.
Ann Oncol, 2014 Feb 07; 25(3). PMID: 24500980    Free PMC article.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.
Georgeta Fried, Mor Moskovitz.
Springerplus, 2014 Feb 26; 3. PMID: 24567880    Free PMC article.
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.
Xi Zhao, Einar Andreas Rødland, +5 authors, Anne-Lise Børresen-Dale.
BMC Cancer, 2014 Mar 22; 14. PMID: 24645668    Free PMC article.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Bahriye Aktas, Agnes Bankfalvi, +2 authors, Sabine Kasimir-Bauer.
Mol Clin Oncol, 2014 Mar 22; 1(6). PMID: 24649291    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients.
S Krenn-Pilko, U Langsenlehner, +5 authors, T Langsenlehner.
Br J Cancer, 2014 Mar 29; 110(10). PMID: 24675383    Free PMC article.
Highly Cited.
An approach to evaluating and comparing biomarkers for patient treatment selection.
Holly Janes, Marshall D Brown, Ying Huang, Margaret S Pepe.
Int J Biostat, 2014 Apr 04; 10(1). PMID: 24695044    Free PMC article.
Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.
Ahmed Bilal Ashraf, Dania Daye, +4 authors, Despina Kontos.
Radiology, 2014 Apr 08; 272(2). PMID: 24702725    Free PMC article.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
P Sinn, S Aulmann, +6 authors, A Schneeweiss.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(9). PMID: 24771945    Free PMC article.
Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer.
Reshma Jagsi, Sarah T Hawley, +7 authors, Steven J Katz.
Cancer, 2014 Apr 30; 120(12). PMID: 24777606    Free PMC article.
The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
William T Barry, Charles M Perou, +2 authors, Joseph G Ibrahim.
J Biopharm Stat, 2014 May 20; 25(1). PMID: 24836519    Free PMC article.
A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer1,2.
Shuang Zhao, S Laura Chang, +2 authors, Gary D Luker.
Transl Oncol, 2014 May 20;. PMID: 24836649    Free PMC article.
Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks.
Lida Zhu, Juan Liu, +2 authors, Jianghui Xiong.
PLoS One, 2014 May 23; 9(5). PMID: 24848634    Free PMC article.
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
Combining biomarkers to optimize patient treatment recommendations.
Chaeryon Kang, Holly Janes, Ying Huang.
Biometrics, 2014 Jun 04; 70(3). PMID: 24889663    Free PMC article.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Review.
An 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer.
Monica Mannelqvist, Elisabeth Wik, Ingunn M Stefansson, Lars A Akslen.
PLoS One, 2014 Jun 07; 9(6). PMID: 24905342    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
How does genome sequencing impact surgery?
Marlies S Reimers, Charla C Engels, +2 authors, Gerrit J Liefers.
Nat Rev Clin Oncol, 2014 Jun 25; 11(10). PMID: 24958181
Review.
Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.
Chirag Shah, Frank A Vicini, +6 authors, Neal Goldstein.
Am J Clin Oncol, 2014 Jul 19; 38(5). PMID: 25036472    Free PMC article.
Review.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Review.
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Anieta M Sieuwerts, Maria B Lyng, +6 authors, Henrik J Ditzel.
Mol Oncol, 2014 Aug 02; 8(8). PMID: 25081647    Free PMC article.
Biological subtypes of breast cancer: Prognostic and therapeutic implications.
Ozlem Yersal, Sabri Barutca.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114856    Free PMC article.
Highly Cited. Review.
Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer.
Qinchuan Wang, Jichun Zhou, +10 authors, Linbo Wang.
Tumour Biol, 2014 Aug 17; 35(11). PMID: 25128063
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Hideko Yamauchi, Chizuko Nakagawa, +9 authors, Seigo Nakamura.
BMC Health Serv Res, 2014 Sep 06; 14. PMID: 25190451    Free PMC article.
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.
Kevin Kalinsky, Emerson A Lim, +10 authors, Dawn L Hershman.
Cancer Invest, 2014 Sep 26; 32(9). PMID: 25254601    Free PMC article.
An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.
N A Meadows, A Morrison, +2 authors, R W Barker.
Pharmacogenomics J, 2014 Oct 08; 15(1). PMID: 25287070
Review.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
Costanza Paoletti, Maria C Muñiz, +13 authors, Daniel F Hayes.
Clin Cancer Res, 2014 Nov 09; 21(11). PMID: 25381338    Free PMC article.
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.
D Balmativola, C Marchiò, +26 authors, A Sapino.
Breast Cancer Res Treat, 2014 Nov 15; 148(3). PMID: 25395316    Free PMC article.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Review.
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Patricia R Blank, Martin Filipits, +11 authors, Michael Gnant.
Pharmacoeconomics, 2014 Nov 19; 33(2). PMID: 25404424    Free PMC article.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
George T Budd, William E Barlow, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2014 Nov 26; 33(1). PMID: 25422488    Free PMC article.
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Michael Marrone, Alison Stewart, W David Dotson.
Genet Med, 2014 Dec 05; 17(7). PMID: 25474343    Free PMC article.
Review.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.
Umar Wazir, Kefah Mokbel.
World J Clin Oncol, 2014 Dec 11; 5(5). PMID: 25493218    Free PMC article.
Association of survivin splice variants with prognosis and treatment of breast cancer.
Anastasia Pavlidou, Christos Kroupis, Kleanthi Dimas.
World J Clin Oncol, 2014 Dec 11; 5(5). PMID: 25493226    Free PMC article.
Review.
Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.
Vanessa B Sheppard, Suzanne C O'Neill, +3 authors, Claudine Isaacs.
Clin Breast Cancer, 2015 Jan 04; 15(2). PMID: 25555816    Free PMC article.
Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.
Adrian Towse, Diego Ossa, +2 authors, Louis Garrison.
J Pers Med, 2013 Jan 01; 3(4). PMID: 25562729    Free PMC article.
Review.
Emerging understanding of multiscale tumor heterogeneity.
Michael J Gerdes, Anup Sood, +3 authors, Fiona Ginty.
Front Oncol, 2015 Jan 08; 4. PMID: 25566504    Free PMC article.
Review.
Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?
Debarshi Jana, Diptendra Kumar Sarkar, +3 authors, Syamsundar Mandal.
Indian J Surg Oncol, 2015 Mar 15; 5(4). PMID: 25767340    Free PMC article.
Ki67--no evidence for its use in node-positive breast cancer.
Fabrice Andre, Monica Arnedos, +2 authors, Suzette Delaloge.
Nat Rev Clin Oncol, 2015 Mar 18; 12(5). PMID: 25781576
Review.
A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer.
Thomas G Frazier, Kevin R Fox, +13 authors, Michael S Broder.
Pharmaceuticals (Basel), 2015 Mar 20; 8(1). PMID: 25789420    Free PMC article.
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Xavier Pivot, Laura Mansi, +14 authors, Christian Villanueva.
Oncologist, 2015 Mar 22; 20(4). PMID: 25795632    Free PMC article.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
C Denkert, B M Pfitzner, B I Heppner, M Dietel.
Pathologe, 2015 Apr 04; 36(2). PMID: 25836324
Review.
Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.
A Eisen, G G Fletcher, +5 authors, members of the Early Breast Cancer Systemic Therapy Consensus Panel.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848340    Free PMC article.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Brian David Lehmann, Yan Ding, +6 authors, Yajun Yi.
BMC Cancer, 2015 Apr 18; 15. PMID: 25886164    Free PMC article.
Molecular characterization and targeted therapeutic approaches in breast cancer.
Angela Toss, Massimo Cristofanilli.
Breast Cancer Res, 2015 Apr 24; 17. PMID: 25902832    Free PMC article.
Review.
Developing a new generation of breast cancer clinical gene expression tests.
Zuzana Kos, Torsten O Nielsen.
Breast Cancer Res, 2014 Jan 01; 16(4). PMID: 25928431    Free PMC article.
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Stian Knappskog, Elisabet O Berge, +16 authors, Per E Lønning.
Mol Oncol, 2015 May 26; 9(8). PMID: 26004085    Free PMC article.
Effects of age on the detection and management of breast cancer.
Andrew McGuire, James A L Brown, +2 authors, Michael J Kerin.
Cancers (Basel), 2015 May 27; 7(2). PMID: 26010605    Free PMC article.
Highly Cited. Review.
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.
Molly Andreason, Chong Zhang, +7 authors, Amye J Tevaarwerk.
J Community Support Oncol, 2015 Jun 02; 13(5). PMID: 26029936    Free PMC article.
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer.
Chao Cheng, Frederick S Varn, Carmen J Marsit.
Mol Cancer Res, 2015 Jun 03; 13(9). PMID: 26032289    Free PMC article.
Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Yi-Zi Zheng, Lei Wang, Xin Hu, Zhi-Ming Shao.
Oncotarget, 2015 Jun 04; 6(26). PMID: 26036636    Free PMC article.
Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Gregory Katz, Olivier Romano, +7 authors, Rémy Salmon.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086912    Free PMC article.
The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.
Holly Janes, Margaret S Pepe, +2 authors, Patrick J Heagerty.
J Natl Cancer Inst, 2015 Jun 26; 107(8). PMID: 26109106    Free PMC article.
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
Joseph Gligorov, Xavier B Pivot, +11 authors, Francilian Breast Intergroup.
Oncologist, 2015 Jun 27; 20(8). PMID: 26112003    Free PMC article.
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
Holly Janes, Marshall D Brown, Margaret S Pepe.
Stat Med, 2015 Jun 27; 34(27). PMID: 26112650    Free PMC article.
Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis.
Xue-Lin Zou, Chun Wang, +2 authors, Zhen-Yu Ding.
Mol Clin Oncol, 2015 Jul 03; 3(3). PMID: 26137280    Free PMC article.
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.
J Ribeiro, B Sousa, F Cardoso.
EJC Suppl, 2013 Sep 01; 11(2). PMID: 26217109    Free PMC article.
Review.
Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer.
Fanny Le Du, Ana M Gonzalez-Angulo, +3 authors, Naoto T Ueno.
Clin Breast Cancer, 2015 Aug 04; 15(6). PMID: 26233757    Free PMC article.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Molecular Determinants of Prognosis in Hepatocellular Carcinoma.
Jean-Charles Nault.
J Clin Transl Hepatol, 2014 Mar 01; 2(1). PMID: 26357615    Free PMC article.
Review.
Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.
Lik Hang Lee, Paul E Swanson, +2 authors, Hua Yang.
Appl Immunohistochem Mol Morphol, 2015 Sep 16; 25(1). PMID: 26371428    Free PMC article.
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
L Rossi, E Laas, +6 authors, F Reyal.
Br J Cancer, 2015 Sep 18; 113(7). PMID: 26379080    Free PMC article.
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.
Vera Jean Suman, Matthew J Ellis, Cynthia X Ma.
Chin Clin Oncol, 2015 Sep 27; 4(3). PMID: 26408301    Free PMC article.
Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Statistical Methods for Establishing Personalized Treatment Rules in Oncology.
Junsheng Ma, Brian P Hobbs, Francesco C Stingo.
Biomed Res Int, 2015 Oct 09; 2015. PMID: 26446492    Free PMC article.
Review.
Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem.
Fotinos-Ioannis D Dimitrakopoulos, Anastasia Kottorou, +2 authors, Haralabos P Kalofonos.
J Breast Cancer, 2015 Oct 17; 18(3). PMID: 26472970    Free PMC article.
Review.
SEOM clinical guidelines in early-stage breast cancer 2015.
J A Garcia-Saenz, B Bermejo, +7 authors, E Ciruelos.
Clin Transl Oncol, 2015 Oct 27; 17(12). PMID: 26497356    Free PMC article.
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis.
Wim Verleyen, Simon P Langdon, +2 authors, V Anne Smith.
Sci Rep, 2015 Oct 28; 5. PMID: 26503707    Free PMC article.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.
Yehoda M Martei, Jennifer M Matro.
Breast Cancer (Dove Med Press), 2015 Oct 28; 7. PMID: 26504408    Free PMC article.
Review.
Chemotherapy and the recurrence score--results as expected?
Lajos Pusztai.
Nat Rev Clin Oncol, 2015 Nov 11; 12(12). PMID: 26552957
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Tara Sanft, Bilge Aktas, +11 authors, Lajos Pusztai.
Breast Cancer Res Treat, 2015 Nov 19; 154(3). PMID: 26578401    Free PMC article.
Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
Andrew J Epstein, Yu-Ning Wong, +6 authors, Peter W Groeneveld.
J Clin Oncol, 2015 Nov 26; 33(36). PMID: 26598749    Free PMC article.
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Megan C Roberts, Morris Weinberger, +5 authors, Stephanie B Wheeler.
J Clin Oncol, 2015 Nov 26; 34(2). PMID: 26598755    Free PMC article.
Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.
Sandra M Swain, Raquel Nunes, +2 authors, Amy P Sing.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610382    Free PMC article.
A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Michael D Alvarado, Che Prasad, +5 authors, Christos J Markopoulos.
Adv Ther, 2015 Nov 28; 32(12). PMID: 26610383    Free PMC article.
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
Melody J Xu, Jay F Dorsey, +7 authors, Gary D Kao.
Oncologist, 2015 Nov 29; 21(1). PMID: 26614709    Free PMC article.
Review.
Biomarkers in Breast Cancer - An Update.
M Schmidt, P A Fasching, M W Beckmann, H Kölbl.
Geburtshilfe Frauenheilkd, 2012 Sep 01; 72(9). PMID: 26640290    Free PMC article.
High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors.
Arvind Thakkar, Hemanth Raj, +3 authors, Muralidhara Padigaru.
Biomark Insights, 2015 Dec 10; 10. PMID: 26648682    Free PMC article.
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
Genet Med, 2015 Dec 19; 18(8). PMID: 26681310
Breast cancer intrinsic subtype classification, clinical use and future trends.
Xiaofeng Dai, Ting Li, +4 authors, Bozhi Shi.
Am J Cancer Res, 2015 Dec 23; 5(10). PMID: 26693050    Free PMC article.
Highly Cited. Review.
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Dennis C Sgroi, Judy-Anne W Chapman, +10 authors, Michael Pollak.
Breast Cancer Res, 2016 Jan 06; 18(1). PMID: 26728744    Free PMC article.
AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.
Roman Hrstka, Pavla Bouchalova, +4 authors, Borivoj Vojtesek.
Mol Oncol, 2016 Jan 07; 10(5). PMID: 26733232    Free PMC article.
A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases.
Vinod P Balachandran, Arshi Arora, +13 authors, Michael I D'Angelica.
Clin Cancer Res, 2016 Jan 07; 22(10). PMID: 26733613    Free PMC article.
Genetic evaluation of male infertility.
Matthew S Wosnitzer.
Transl Androl Urol, 2014 Mar 01; 3(1). PMID: 26813518    Free PMC article.
Review.
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.
Romualdo Barroso-Sousa, Danilo D A Fonseca Reis Silva, Joao Victor Machado Alessi, Max Senna Mano.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823678    Free PMC article.
Review.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Review.
Patterns in target-directed breast cancer research.
Sofia Torres, Christine Simmons, +3 authors, Maureen Trudeau.
Springerplus, 2016 Feb 16; 5. PMID: 26877907    Free PMC article.
Role of Combined Sentinel Lymph Node Biopsy and Axillary Node Sampling in Clinically Node-Negative Breast Cancer.
K J Edwards, M A Dordea, R French, V Kurup.
Indian J Surg, 2016 Feb 18; 77(6). PMID: 26884657    Free PMC article.
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
Enora Laas, Peter Mallon, +3 authors, Fabien Reyal.
PLoS One, 2016 Feb 20; 11(2). PMID: 26895349    Free PMC article.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res Treat, 2016 Feb 26; 156(1). PMID: 26909792    Free PMC article.
Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Eunjin Jwa, Kyung Hwan Shin, +8 authors, Tae Hyun Kim.
Cancer Res Treat, 2016 Oct 19; 48(4). PMID: 26910473    Free PMC article.
The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Anna Kuchel, Tim Robinson, +8 authors, Jeremy P Braybrooke.
Br J Cancer, 2016 Mar 10; 114(7). PMID: 26954715    Free PMC article.
Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.
Floor J Backes, Christopher J Walker, +5 authors, Adrian A Suarez.
Gynecol Oncol, 2016 Mar 10; 141(2). PMID: 26957478    Free PMC article.
Translating RNA sequencing into clinical diagnostics: opportunities and challenges.
Sara A Byron, Kendall R Van Keuren-Jensen, +2 authors, David W Craig.
Nat Rev Genet, 2016 Mar 22; 17(5). PMID: 26996076    Free PMC article.
Highly Cited. Review.
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
Tari A King, Jaclyn P Lyman, +17 authors, Clifford A Hudis.
J Clin Oncol, 2016 Mar 24; 34(20). PMID: 27001590    Free PMC article.
Long-term exposure of MCF-12A normal human breast epithelial cells to ethanol induces epithelial mesenchymal transition and oncogenic features.
Robert Gelfand, Dolores Vernet, +2 authors, Nestor F Gonzalez-Cadavid.
Int J Oncol, 2016 Apr 02; 48(6). PMID: 27035792    Free PMC article.
Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.
David D Chism, W Kimryn Rathmell.
Nat Rev Nephrol, 2016 Apr 26; 12(6). PMID: 27108841    Free PMC article.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
John M S Bartlett, Jane Bayani, +18 authors, OPTIMA TMG.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130929    Free PMC article.
Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Kathrin Halfter, Oliver Hoffmann, +6 authors, Barbara Mayer.
J Transl Med, 2016 May 05; 14(1). PMID: 27142386    Free PMC article.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Su Hyun Lee, Seunggyun Ha, +9 authors, Gi Jeong Cheon.
Eur J Nucl Med Mol Imaging, 2016 May 23; 43(9). PMID: 27209424
Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound.
Amy E Cyr, Natalia Tucker, +8 authors, William E Gillanders.
J Am Coll Surg, 2016 May 24; 223(2). PMID: 27212005    Free PMC article.
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Norman Wolmark, Eleftherios P Mamounas, +6 authors, Soonmyung Paik.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217450    Free PMC article.
Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.
Anosheh Afghahi, Maya Mathur, +14 authors, Allison W Kurian.
J Oncol Pract, 2016 May 26; 12(6). PMID: 27221993    Free PMC article.
The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
Josee-Lyne Ethier, Eitan Amir.
Mol Diagn Ther, 2016 May 29; 20(4). PMID: 27235162
Review.
Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.
Jeanette Muniz, Kelley M Kidwell, N Lynn Henry.
Breast Cancer Res Treat, 2016 Jun 09; 157(3). PMID: 27271766    Free PMC article.
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Jessica G Cockburn, Robin M Hallett, +5 authors, Anita Bane.
BMC Cancer, 2016 Jul 30; 16. PMID: 27469239    Free PMC article.
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Hannah Y Wen, Melissa Krystel-Whittemore, +7 authors, Edi Brogi.
Cancer, 2016 Aug 16; 123(1). PMID: 27526056    Free PMC article.
Luminal B breast cancer: patterns of recurrence and clinical outcome.
Zhi-Hua Li, Ping-Hua Hu, Jian-Hong Tu, Ni-Si Yu.
Oncotarget, 2016 Aug 20; 7(40). PMID: 27542253    Free PMC article.
SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer.
Lauren L Siewertsz van Reesema, Vasilena Zheleva, +17 authors, Amy H Tang.
EBioMedicine, 2016 Aug 30; 11. PMID: 27569656    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?
Sandra Casimiro, Arlindo R Ferreira, +2 authors, Luis Costa.
Int J Mol Sci, 2016 Sep 14; 17(9). PMID: 27618899    Free PMC article.
Review.
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice.
S Michiels, N Ternès, F Rotolo.
Ann Oncol, 2016 Sep 17; 27(12). PMID: 27634691    Free PMC article.
Review.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
Best Practices for Genomic Assay Testing in Early-Stage Breast Cancer: Clinical and Medicolegal Perspectives.
Andrew D Seidman, Darius K Amjadi, Tammy De La Melena, Darren Wheeler.
Popul Health Manag, 2016 Sep 30; 20(4). PMID: 27684734    Free PMC article.
mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.
E P van der Stok, M Smid, +6 authors, C Verhoef.
Mol Oncol, 2016 Oct 04; 10(10). PMID: 27692894    Free PMC article.
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Flora Stavridi, Konstantine T Kalogeras, +19 authors, George Fountzilas.
PLoS One, 2016 Oct 04; 11(10). PMID: 27695115    Free PMC article.
The analytical validation of the Oncotype DX Recurrence Score assay.
Frederick L Baehner.
Ecancermedicalscience, 2016 Oct 13; 10. PMID: 27729940    Free PMC article.
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
Xiaolan Feng, Haocheng Li, +9 authors, Alexander Paterson.
Oncotarget, 2016 Oct 16; 7(52). PMID: 27741524    Free PMC article.
Major clinical research advances in gynecologic cancer in 2015.
Dong Hoon Suh, Miseon Kim, +2 authors, Jae Weon Kim.
J Gynecol Oncol, 2016 Oct 25; 27(6). PMID: 27775259    Free PMC article.
Review.
Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
Christopher R Friese, Yun Li, +6 authors, Steven J Katz.
Cancer, 2016 Oct 25; 123(1). PMID: 27775837    Free PMC article.
Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.
Junsheng Ma, Brian P Hobbs, Francesco C Stingo.
Stat Methods Med Res, 2016 Nov 04; 27(7). PMID: 27807177    Free PMC article.
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
Weige Tan, Wei Luo, +6 authors, Chang Gong.
Oncotarget, 2016 Nov 29; 7(52). PMID: 27894097    Free PMC article.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Christopher D Hart, Alessia Vignoli, +9 authors, Angelo Di Leo.
Clin Cancer Res, 2017 Jan 14; 23(6). PMID: 28082280    Free PMC article.
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer.
Int J Breast Cancer, 2017 Feb 09; 2017. PMID: 28168058    Free PMC article.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Kaixian Yu, Qing-Xiang Amy Sang, +6 authors, Jinfeng Zhang.
Sci Rep, 2017 Mar 04; 7. PMID: 28256629    Free PMC article.
Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.
Sean P Pitroda, Riyue Bao, +2 authors, Philip P Connell.
Clin Cancer Res, 2017 Mar 28; 23(15). PMID: 28341751    Free PMC article.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
Jiayi Wu, Yan Fang, +11 authors, Kunwei Shen.
Oncotarget, 2017 Apr 14; 8(24). PMID: 28404972    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Bernhard C Pestalozzi, Christoph Tausch, +17 authors, Swiss Group for Clinical Cancer Research (SAKK).
BMC Cancer, 2017 Apr 15; 17(1). PMID: 28407750    Free PMC article.
Limitations of Personalized Medicine and Gene Assays for Breast Cancer.
David Tiberi, Laura Masucci, +5 authors, Philip Wong.
Cureus, 2017 Apr 22; 9(3). PMID: 28428927    Free PMC article.
Towards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.
Daniel M Trifiletti, Vanessa N Sturz, Timothy N Showalter, Jennifer M Lobo.
PLoS One, 2017 May 10; 12(5). PMID: 28486497    Free PMC article.
Systematic Review.
A high-throughput method to detect RNA profiling by integration of RT-MLPA with next generation sequencing technology.
Jing Wang, Xue Yang, +5 authors, Jidong Gao.
Oncotarget, 2017 May 26; 8(28). PMID: 28545022    Free PMC article.
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.
Daniel J Farrugia, Alessandra Landmann, +13 authors, Rohit Bhargava.
Mod Pathol, 2017 May 27; 30(8). PMID: 28548119
Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
Sungmin Park, Se Kyung Lee, +7 authors, Seok Jin Nam.
Medicine (Baltimore), 2017 Jun 01; 96(22). PMID: 28562530    Free PMC article.
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Review.
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Gulisa Turashvili, Joanne F Chou, +5 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jul 14; 166(1). PMID: 28702894    Free PMC article.
Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease.
Jyothi S Prabhu, Aruna Korlimarla, +14 authors, T S Sridhar.
Transl Oncol, 2017 Jul 14; 10(4). PMID: 28704710    Free PMC article.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology.
Elizabeth A Mittendorf, Mariana Chavez-MacGregor, +5 authors, Kelly K Hunt.
Ann Surg Oncol, 2017 Jul 21; 24(12). PMID: 28726077    Free PMC article.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Laura J van 't Veer, Christina Yau, +6 authors, Linda Sofie Lindström.
Breast Cancer Res Treat, 2017 Aug 05; 166(2). PMID: 28776283    Free PMC article.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.
Holly Janes, Marshall D Brown, +2 authors, William E Barlow.
Contemp Clin Trials, 2017 Aug 19; 63. PMID: 28818434    Free PMC article.
Cancer Care at Times of Crisis and War: The Syrian Example.
Eman Sahloul, Riad Salem, +4 authors, M Bassel Atassi.
J Glob Oncol, 2017 Aug 24; 3(4). PMID: 28831442    Free PMC article.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Ana C Gregório, Manuela Lacerda, +3 authors, João Nuno Moreira.
Pathol Oncol Res, 2017 Sep 16; 24(4). PMID: 28913723
Review.
Prognostic immune-related gene models for breast cancer: a pooled analysis.
Jianli Zhao, Ying Wang, +6 authors, Kai Chen.
Onco Targets Ther, 2017 Oct 06; 10. PMID: 28979134    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
Michaela Tsai, Shelly Lo, +11 authors, Hatem Soliman.
JAMA Oncol, 2017 Oct 28; 4(1). PMID: 29075751    Free PMC article.
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
E Nilüfer Güler.
Eur J Breast Health, 2017 Oct 31; 13(4). PMID: 29082373    Free PMC article.
Review.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.
Volker Möbus, Susanne Hell, Marcus Schmidt.
Geburtshilfe Frauenheilkd, 2017 Nov 03; 77(10). PMID: 29093601    Free PMC article.
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Andrew Dodson, David Okonji, +6 authors, Mitch Dowsett.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128896    Free PMC article.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, +14 authors, Norman Wolmark.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128898    Free PMC article.
Molecular Subtypes and Local-Regional Control of Breast Cancer.
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss.
Surg Oncol Clin N Am, 2017 Nov 15; 27(1). PMID: 29132568    Free PMC article.
Review.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, +15 authors, PierFranco Conte.
Oncologist, 2017 Nov 15; 23(3). PMID: 29133514    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Review.
Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
Oluwadamilola M Fayanju, Ko Un Park, Anthony Lucci.
Ann Surg Oncol, 2017 Nov 22; 25(2). PMID: 29159748    Free PMC article.
Review.
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Tissue-based biomarkers in prostate cancer.
Timothy N Clinton, Aditya Bagrodia, +3 authors, Solomon L Woldu.
Expert Rev Precis Med Drug Dev, 2017 Dec 12; 2(5). PMID: 29226251    Free PMC article.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.
Pu Cheng, Zhen Wang, +3 authors, Jian Huang.
Oncotarget, 2017 Dec 22; 8(61). PMID: 29262565    Free PMC article.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Review.
Structured detection of interactions with the directed lasso.
Hristina Pashova, Michael LeBlanc, Charles Kooperberg.
Stat Biosci, 2018 Jan 03; 9(2). PMID: 29292402    Free PMC article.
The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
Satbir Singh Thakur, Haocheng Li, +5 authors, Hua Yang.
PLoS One, 2018 Jan 06; 13(1). PMID: 29304138    Free PMC article.
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
BMC Cancer, 2018 Jan 07; 18(1). PMID: 29304773    Free PMC article.
Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment.
Corey Speers, Lori J Pierce.
Int J Breast Cancer, 2018 Jan 20; 2017. PMID: 29348942    Free PMC article.
Review.
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, +7 authors, Andrea Eisen.
Oncologist, 2018 Jan 27; 23(7). PMID: 29371476    Free PMC article.
Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.
Yehoda M Martei, Lydia E Pace, Jane E Brock, Lawrence N Shulman.
Clin Lab Med, 2018 Feb 08; 38(1). PMID: 29412880    Free PMC article.
Review.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.
Onur Esbah, Berna Oksuzoglu.
Indian J Med Res, 2018 Mar 08; 146(5). PMID: 29512598    Free PMC article.
Review.
The 21-Gene Recurrence Score in Male Breast Cancer.
Gulisa Turashvili, Monica Gonzalez-Loperena, +4 authors, Hannah Y Wen.
Ann Surg Oncol, 2018 Mar 10; 25(6). PMID: 29520654    Free PMC article.
Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis.
Haiyan Gao, Mei Yang, Xiaolan Zhang.
Oncol Lett, 2018 Mar 17; 15(4). PMID: 29545900    Free PMC article.
Validation of Memorial Sloan Kettering Cancer Center nomogram to detect non-sentinel lymph node metastases in a United Kingdom cohort.
A Syed, S Eleti, +2 authors, H Thomas.
G Chir, 2018 Mar 20; 39(1). PMID: 29549676    Free PMC article.
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Alfred Massarweh, George W Sledge, +3 authors, Steven Shak.
J Clin Oncol, 2018 Mar 28; 36(14). PMID: 29584547    Free PMC article.
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
Purificación Martínez Del Prado, Isabel Alvarez-López, +7 authors, Javier Mar.
Clinicoecon Outcomes Res, 2018 Mar 30; 10. PMID: 29593426    Free PMC article.
Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.
S Aggarwal, A Vaid, +10 authors, D Doval.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721472    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Spinal cord injured women's treatment of breast carcinoma: alert to complications.
Ashley L de Padua, Kimberly Strickland, Mary Patrick, John F Ditunno.
Spinal Cord Ser Cases, 2018 May 31; 4. PMID: 29844929    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score.
Feilin Qu, Xiaosong Chen, +10 authors, Kunwei Shen.
Chin J Cancer Res, 2018 Jun 05; 30(2). PMID: 29861607    Free PMC article.
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
Kivilcim Ozturk, Michelle Dow, +2 authors, Hannah Carter.
J Mol Biol, 2018 Jun 18; 430(18 Pt A). PMID: 29908887    Free PMC article.
Review.
Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.
Yi Cui, Bailiang Li, +2 authors, Ruijiang Li.
Clin Cancer Res, 2018 Jun 21; 24(19). PMID: 29921729    Free PMC article.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.
Rodney F Minchin, Neville J Butcher.
BMC Genomics, 2018 Jul 05; 19(1). PMID: 29969986    Free PMC article.
Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification.
Xiang Ren, Parham Ghassemi, +6 authors, Masoud Agah.
ACS Sens, 2018 Jul 07; 3(8). PMID: 29979037    Free PMC article.
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Yun Yeong Kim, Se Jeong Oh, +2 authors, Heung Kyu Park.
PLoS One, 2018 Jul 07; 13(7). PMID: 29979736    Free PMC article.
Personalizing Radiation Treatment Delivery in the Management of Breast Cancer.
Kamran A Ahmed, G Daniel Grass, +7 authors, Roberto Diaz.
Int J Breast Cancer, 2018 Jul 10; 2018. PMID: 29984003    Free PMC article.
Review.
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Maj-Britt Jensen, Anne-Vibeke Lænkholm, +7 authors, Bent Ejlertsen.
Breast Cancer Res, 2018 Jul 29; 20(1). PMID: 30053900    Free PMC article.
Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
Audree B Tadros, Hannah Y Wen, Monica Morrow.
Ann Surg Oncol, 2018 Aug 11; 25(11). PMID: 30094484    Free PMC article.
Overview of Breast Cancer Therapy.
Tracy-Ann Moo, Rachel Sanford, Chau Dang, Monica Morrow.
PET Clin, 2018 Aug 14; 13(3). PMID: 30100074    Free PMC article.
Review.
Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.
Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel.
Int J Breast Cancer, 2018 Aug 17; 2018. PMID: 30112216    Free PMC article.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Hans-Ullrich Völker, Michael Weigel, Annette Strehl, Lea Frey.
Diagn Pathol, 2018 Sep 02; 13(1). PMID: 30170623    Free PMC article.
An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
André Filipe Vieira, Fernando Schmitt.
Front Med (Lausanne), 2018 Sep 21; 5. PMID: 30234119    Free PMC article.
Review.
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wei Wang, Xiaosong Chen, +12 authors, Kunwei Shen.
J Cancer, 2018 Oct 03; 9(18). PMID: 30271480    Free PMC article.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Review.
Development of biomarkers for real precision medicine.
Masahiro Shibata, Mohammad Obaidul Hoque.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393609    Free PMC article.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark.
NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases.
Wei-Rong Chen, Jia-Peng Deng, +3 authors, San-Gang Wu.
Cancer Res Treat, 2019 Mar 28; 51(4). PMID: 30913871    Free PMC article.
Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Shuning Ding, Jiayi Wu, +6 authors, Li Zhu.
Oncologist, 2019 Apr 26; 24(11). PMID: 31019021    Free PMC article.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Lindsay J Collin, Ming Yan, +8 authors, Lauren E McCullough.
NPJ Breast Cancer, 2019 Oct 05; 5. PMID: 31583272    Free PMC article.
Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.
Qing-Hong Zhang, Wen-Wen Zhang, +4 authors, San-Gang Wu.
Ann Transl Med, 2019 Nov 09; 7(18). PMID: 31700882    Free PMC article.
Cost-utility analysis of 21-gene assay for node-positive early breast cancer.
L Masucci, S Torres, +5 authors, W Isaranuwatchai.
Curr Oncol, 2019 Nov 12; 26(5). PMID: 31708649    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Breast Cancer Recurrence Risk Assessment: Is Non-Invasive Monitoring an Option?
Elisa M Schunkert, Wanzhou Zhao, Kurt Zänker.
Biomed Hub, 2018 Nov 01; 3(3). PMID: 31988964    Free PMC article.
Review.
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Wendy A Woodward, William E Barlow, +15 authors, Kathy S Albain.
JAMA Oncol, 2020 Jan 10; 6(4). PMID: 31917424    Free PMC article.
Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers.
Ming Luo, Fu Li, +2 authors, Jian Zeng.
Cancer biology & therapy, 2019 Oct 31; 21(2). PMID: 31663437    Free PMC article.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands.
Kay Schreuder, Anne Kuijer, +2 authors, Sabine Siesling.
Public Health Genomics, 2019 Jan 17; 21(1-2). PMID: 30650410    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.
Stephen Shuford, Christine Wilhelm, +22 authors, Teresa M DesRochers.
Sci Rep, 2019 Aug 03; 9(1). PMID: 31371750    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Andreana N Holowatyj, Michele L Cote, +5 authors, Kristen S Purrington.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29341832    Free PMC article.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
Maj-Britt Jensen, Anne-Vibeke Lænkholm, +9 authors, Bent Ejlertsen.
NPJ Breast Cancer, 2020 Mar 07; 6. PMID: 32140564    Free PMC article.
Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making.
Emily Ross, Julia Swallow, Anne Kerr, Sarah Cunningham-Burley.
Health Expect, 2018 Nov 06; 22(1). PMID: 30387238    Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.
Liping Tan, Dongmei Mai, +17 authors, Dongxin Lin.
Mol Cancer, 2019 Jan 15; 18(1). PMID: 30636640    Free PMC article.
Highly Cited.
Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Manjiri M Bakre, Charusheila Ramkumar, +10 authors, Mark D Pegram.
Cancer Med, 2019 Mar 09; 8(4). PMID: 30848103    Free PMC article.
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Mustapha Abubakar, Jonine Figueroa, +8 authors, Paul D Pharoah.
Mod Pathol, 2019 Apr 13; 32(9). PMID: 30976105    Free PMC article.
Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.
Ang Zheng, Lin Zhang, +2 authors, Feng Jin.
Am J Mens Health, 2019 May 10; 13(3). PMID: 31068065    Free PMC article.
Review.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Ki-67, an elusive marker in the prognosis of breast cancer.
Neelam Sood.
Indian J Med Res, 2019 Nov 14; 150(3). PMID: 31719290    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
The Correlation of Magee EquationsTM and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer.
Atilla Soran, Kaori Tane, Efe Sezgin, Rohit Bhargava.
Eur J Breast Health, 2020 Apr 15; 16(2). PMID: 32285033    Free PMC article.
Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study.
Yanna Zhang, Yidong Zhou, +2 authors, Qiang Sun.
Cancer Commun (Lond), 2020 Apr 16; 40(4). PMID: 32291973    Free PMC article.
Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.
David Krug, René Baumann, +12 authors, Rolf Sauer.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398980    Free PMC article.
Review.
21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort.
J Bryan Iorgulescu, Rachel A Freedman, +2 authors, Jane E Brock.
JCO Precis Oncol, 2019 Jan 01; 3. PMID: 32457931    Free PMC article.
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Hee Jeong Kim, Woo Chul Noh, +7 authors, Sei Hyun Ahn.
Breast Cancer Res, 2020 May 29; 22(1). PMID: 32460816    Free PMC article.
Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Sumadi Lukman Anwar, Widya Surya Avanti, +5 authors, Wahyu Wulaningsih.
World J Surg Oncol, 2020 Jun 01; 18(1). PMID: 32473643    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
RDGN-based predictive model for the prognosis of breast cancer.
Bing Dong, Ming Yi, +2 authors, Kongming Wu.
Exp Hematol Oncol, 2020 Jun 19; 9. PMID: 32550045    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.
Rachel A Freedman, Mina S Sedrak, +8 authors, Eric P Winer.
J Natl Cancer Inst, 2020 May 26;. PMID: 32449757    Free PMC article.
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Daniel A Goldstein, Chen Mayer, +5 authors, Hadar Goldvaser.
Cancer Med, 2020 May 07; 9(13). PMID: 32372569    Free PMC article.
Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER.
Z Sun, A Prat, +2 authors, C M Perou.
Ann Oncol, 2014 Oct 31; 26(1). PMID: 25355719    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review.
Sophie Gordon-Craig, Ruth M Parks, Kwok-Leung Cheung.
Oncol Ther, 2020 Jul 24; 8(2). PMID: 32700048    Free PMC article.
Review.
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Aurelia Noske, Sophie-Isabelle Anders, +6 authors, Evelyn Klein.
Breast, 2019 Dec 02; 49. PMID: 31786414    Free PMC article.
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.
Alberto Zambelli, Edda Simoncini, +11 authors, Carlo Tondini.
Breast, 2020 Apr 24; 52. PMID: 32325372    Free PMC article.
Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Garazi Serna, Sara Simonetti, +10 authors, Paolo Nuciforo.
Breast, 2020 Jul 25; 53. PMID: 32707454    Free PMC article.
A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
Barbara L Smith, Anvy Nguyen, +6 authors, Michele A Gadd.
Breast Cancer Res Treat, 2020 Jul 28; 183(3). PMID: 32712878    Free PMC article.
Review.
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study.
Jiayi Wu, Shuning Ding, +16 authors, Li Zhu.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019280    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Sarah M Bernhardt, Pallave Dasari, +6 authors, Wendy V Ingman.
Breast Cancer Res, 2020 Aug 20; 22(1). PMID: 32811558    Free PMC article.
Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.
Shaoyan Lin, Hongnan Mo, +14 authors, Binghe Xu.
Breast, 2020 Aug 25; 53. PMID: 32836201    Free PMC article.
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Susan K Boolbol, Manju Harshan, +8 authors, Stephen Malamud.
Breast Cancer Res Treat, 2019 Jul 16; 177(3). PMID: 31302854    Free PMC article.
Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors.
Nobuyuki Arima, Reiki Nishimura, +5 authors, Yasuo Toyozumi.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655808    Free PMC article.
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
Jinkyoung Kim, Aeree Kim, Chungyeul Kim.
Oncol Lett, 2019 Jan 25; 17(2). PMID: 30675242    Free PMC article.
Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer.
San-Gang Wu, Wen-Wen Zhang, +3 authors, Zhen-Yu He.
Onco Targets Ther, 2019 Apr 10; 12. PMID: 30962690    Free PMC article.
21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer.
Wen-Wen Zhang, Qin Tong, +8 authors, Huan-Xin Lin.
Front Oncol, 2019 May 02; 9. PMID: 31041190    Free PMC article.
Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.
Lizhe Zhu, Nan Ma, +5 authors, Yu Ren.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186766    Free PMC article.
Molecular Decision Tree Algorithms Predict Individual Recurrence Pattern for Locally Advanced Nasopharyngeal Carcinoma.
Hongmin Cai, Xiaolin Pang, +14 authors, Jian Zheng.
J Cancer, 2019 Jul 12; 10(15). PMID: 31293635    Free PMC article.
Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
Vahit Özmen, Burcu Çakar, +7 authors, Pınar Saip.
Eur J Breast Health, 2019 Jul 18; 15(3). PMID: 31312795    Free PMC article.
Big Data Approaches for Modeling Response and Resistance to Cancer Drugs.
Peng Jiang, William R Sellers, X Shirley Liu.
Annu Rev Biomed Data Sci, 2019 Jul 26; 1. PMID: 31342013    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.
Li-Tong Yao, Mo-Zhi Wang, +5 authors, Ying-Ying Xu.
World J Clin Cases, 2019 Aug 20; 7(15). PMID: 31423426    Free PMC article.
Review.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
Debbie M Jakubowski, Helen Bailey, +7 authors, Frederick L Baehner.
J Surg Oncol, 2020 Jun 05;. PMID: 32497318    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples.
Yulia Newton, Andrew J Sedgewick, +7 authors, Charles Vaske.
Sci Rep, 2020 Oct 21; 10(1). PMID: 33077815    Free PMC article.
ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer.
Yajie Gong, Nanlin Hu, +18 authors, Peng Yuan.
Front Oncol, 2020 Oct 27; 10. PMID: 33102228    Free PMC article.
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
Aubriana M McEvoy, Steven Poplack, +7 authors, William E Gillanders.
Breast Cancer Res Treat, 2020 Jul 12; 183(2). PMID: 32651755    Free PMC article.
Review.
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Thomas M Schwedhelm, Judy R Rees, +4 authors, Erika L Moen.
BMC Cancer, 2020 Sep 05; 20(1). PMID: 32883270    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.
Landmark trials in the medical oncology management of early stage breast cancer.
Whitney Hensing, Cesar A Santa-Maria, Lindsay L Peterson, Jennifer Y Sheng.
Semin Oncol, 2020 Sep 17; 47(5). PMID: 32933761    Free PMC article.
Review.
Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study.
Katsuhiro Yoshikawa, Mitsuaki Ishida, +3 authors, Tomoharu Sugie.
PLoS One, 2020 Nov 18; 15(11). PMID: 33201923    Free PMC article.